title: Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease.
abstract: Data on dolutegravir removal by hemodialysis are lacking. To study this, we measured dolutegravir plasma concentrations in samples of blood entering and leaving the dialyzer and of the resulting dialysate from 5 HIV-infected patients with end-stage renal disease. The median dolutegravir hemodialysis extraction ratio was 7%. The dolutegravir concentrations after the dialysis session remained far above the protein-binding-adjusted inhibitory concentration. Our results show minimal dolutegravir removal by hemodialysis, with no specific dolutegravir dosage adjustments required in this setting. (This study is registered at ClinicalTrials.gov under registration number NCT02487706.).
authors: Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain Universitat Autónoma de Barcelona (UAB), Barcelona, Spain jmolto@flsida.org.
authors: José
authors: J
authors: Moltó
authors: Nephrology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
authors: Fredzzia
authors: F
authors: Graterol
authors: Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
authors: Cristina
authors: C
authors: Miranda
authors: Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom.
authors: Saye
authors: S
authors: Khoo
authors: Nephrology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
authors: Ioana
authors: I
authors: Bancu
authors: Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom.
authors: Alieu
authors: A
authors: Amara
authors: Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
authors: Anna
authors: A
authors: Bonjoch
authors: Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain Universitat Autónoma de Barcelona (UAB), Barcelona, Spain Universitat de Vic (UVic), Vic, Spain IrsiCaixa Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
authors: Bonaventura
authors: B
authors: Clotet
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D023241:Antiretroviral Therapy, Highly Active; D015314:Dialysis Solutions / Q000737:chemistry*; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006575:Heterocyclic Compounds, 3-Ring / Q000493:pharmacokinetics* / Q000494:pharmacology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000503:physiopathology / Q000628:therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D006435:Renal Dialysis; D016896:Treatment Outcome; D000099226:Dolutegravir
chemical_list: D019380:Anti-HIV Agents; D015314:Dialysis Solutions; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir